Sunday, June 22, 2014 10:23:53 PM
http://www.lctglobal.com/upload/news/pdfs/140623%20LCT%20Parkinsons%20trial%20resumes%20patient%20recruitment.pdf
Living Cell Technologies Limited has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.
Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.
“The completion of the clinical trial is an initial step in progressing NTCELL to commercialization as the first disease modifying treatment for Parkinson’s disease.”
Read the full announcement here.
Never buy/sell based on my posts.My posts are opinions
only.My positions are subject to change W/O
notice NOTICE: NSA reportedly monitors,copies,and
captures IP address of electronic communications to and from the USA.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM